Trials / Completed
CompletedNCT00986401
Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects
Safety and Tolerability of Trospium Chloride Metformin Hydrochloride in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trospium Chloride (Sanctura XR®) | extended release, 60 mg, oral daily |
| DRUG | Metformin hydrochloride (Glucophage®) | immediate release, 500mg |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2009-09-30
- Last updated
- 2011-12-19
- Results posted
- 2011-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00986401. Inclusion in this directory is not an endorsement.